BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 11212241)

  • 21. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
    Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
    Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
    Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
    Yang CJ; Horton JK; Cowan KH; Schneider E
    Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I.
    Chen AY; Shih SJ; Hsiao M; Rothenberg ML; Prudhomme M
    Mol Pharmacol; 2004 Sep; 66(3):553-60. PubMed ID: 15322247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
    Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
    J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
    Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
    Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
    Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
    Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
    Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
    Yoshinari T; Yamada A; Uemura D; Nomura K; Arakawa H; Kojiri K; Yoshida E; Suda H; Okura A
    Cancer Res; 1993 Feb; 53(3):490-4. PubMed ID: 8381047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
    Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
    J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
    Arakawa Y; Ozaki K; Okawa Y; Yamada H
    Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
    Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
    Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
    Lotito L; Russo A; Bueno S; Chillemi G; Fogli MV; Capranico G
    Eur J Pharmacol; 2009 Jan; 603(1-3):29-36. PubMed ID: 19094980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.